Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-27 23:52:33 - browse：63

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： How neuroscience research could help beat back brain cancer

WSS

Police still searching for prisoner who escaped from NYC hospital

The best solution to the drug shortages problem

Medicare proceeds with plan to claw back hospital funds

Coloradans with cystic fibrosis could lose access to Trikafta

Brain injuries and the importance of a second opinion

Coloradans with cystic fibrosis could lose access to Trikafta

hotspot

Wikipedia

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Lung cancer screening guidelines updated for cigarette smokers

Activists slam private health insurers over coverage restrictions

Police still searching for prisoner who escaped from NYC hospital

How to save PrEP access — and even expand it

South Korea throws huge K

In Memoriam: Notable people who died in 2023

Methadone doses haven’t kept up in the age of fentanyl

How one medical school became remarkably diverse

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

knowledge

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Inari Medical to buy amputation prevention company LimFlow

Why failed clinical trials don’t always spell doom for a new drug

Why failed clinical trials don’t always spell doom for a new drug

Humans aren't the only ones with an imagination. Rats have it too

Man killed during FBI raid in connection with threats against Biden, other officials

hotspot

hotspot

hotspot

hotspot